Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 13, 2003 - Issue 1
Submit an article Journal homepage
44
Views
6
CrossRef citations to date
0
Altmetric
Review

Therapeutic potential of potassium channel modulators for CNS disorders

Alan G Clark Lead Discovery Pharmacology,, Organon Laboratories Ltd, Newhouse, Lanarkshire, ML1 5SH, Scotland
,
Susan E Booth Lead Discovery Pharmacology,, Organon Laboratories Ltd, Newhouse, Lanarkshire, ML1 5SH, Scotland
&
John A Morrow Lead Discovery Pharmacology,, Organon Laboratories Ltd, Newhouse, Lanarkshire, ML1 5SH, Scotland
Pages 23-32 | Published online: 02 Mar 2005

Bibliography

  • SHIEH CC, COGHLAN M, SULLIVAN JP, GOPALAKRISHNAN M: Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol. Rev (2000) 52:557–594.
  • ••Excellent review of K+ channel function inthe context of disease.
  • CHANDY KG, GUTMAN GA: Voltage-gated potassium channels. In: Ligand and Voltage-Gated Ion Channels, North A (ed.), Boca Raton, Fl., CRC Press (1995) 1–71.
  • ••A comprehensive review of voltage-gated K+channels.
  • REIMANN F, ASHCROFT FM: Inwardlyrectifying potassium channels. Curt: Opin. Cell Biol. (1999) 11:503–508.
  • WAXMAN SG: Transcriptional channelopathies: an emerging class of disorders. Nat. Rev Neurosci. (2001) 2:652–659.
  • JAN LY, BARBELS, TIMPE L et al.: Mutating a gene for a potassium channel by hybrid dysgenesis: an approach to the cloning of the Shaker locus in Drosophila. Cold Spring Harb. Symp. Quant. Biol. (1983) 48(1):233–245.
  • COOPER EC: Potassium channels: how genetic studies of epileptic syndromes open paths to new therapeutic targets and drugs. Epilepsia (2001) 42 (Supp1.5) : 49–54.
  • WANG HS, PAN Z, SHI Wet al: KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science (1998) 282: 1890-1893.
  • VERGARA C, LATORRE R, MARRION NV, ADELMAN JP: Calcium-activated potassium channels. Curr. Opin. Neurobiol. (1998) 8:321–329.
  • •Useful review of calcium-activted K+ channels.
  • GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI: The pharmacology and molecular biology of large-conductance calcium-activated (BK) potassium channels. Adv. Pharmacol. (1997) 37:319–348.
  • GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI: Maxi-K potassium channels: form, function, and modulation of a class of endogenous regulators of intracellular calcium. Neuroscientist (2001) 7:166–177.
  • STARRETT JE, Jr., DWORETZKY SI, GRIBKOFF VK: Modulators of large-conductance calcium-activated potassium (B K) channels as potential therapeutic targets. Curr. Pharm. Design (1996) 2:413–428.
  • TAMURA A, GRAHAM DI, MCCULLOCH J, TEASDALE GM: Focal cerebral ischaemia in the rat: 1. Description of technique and early neuropathological consequences following middle cerebral artery occlusion. Cereb. Blood Flow Metal,. (1981) 1:53–60.
  • CHENEY JA, WEISSER JD, BAREYRE FM et al.: The maxi-K channel opener BMS-204352 attenuates regional cerebral edema and neurologic motor impairment after experimental brain injury. J. Cereb. Blood Flow Metab. (2001) 21:396–403.
  • GRIBKOFF VK, STARRETT JE Jr, DWORETZKY SI et al.: Targeting acute ischemic stroke with a calcium-sensitive opener of maxi-K potassium channels. Nat. Med. (2001) 7:471–477.
  • DUPUIS DS, SCHRODER RL, JESPERSEN T et al: Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352. Eur. Pharmacol. (2002) 437:129–137.
  • SCHRODER RL, JESPERSEN T, CHRISTOPHERSEN P et al.: KCNQ4 channel activation by BMS-204352 and retigabine. Neuropharmacology (2001) 40:888–898.
  • CASTLE NA: Recent advances in the biology of small conductance calcium-activated potassium channels. Perspectives M Drug Discovery and Design (1999) 15/16:131–154.
  • SHAH M, HAYLETT DG: The pharmacology of hSK1 Ca2±-activated K+ channels expressed in mammalian cell lines. Br. J. Pharmacol. (2000) 129:627–630.
  • VAN DER STAAY FJ, FANELLI, RJ, BLOKLAND A, SCHMIDT BH: Behavioral effects of apamin, a selective inhibitor of the SK(Ca)-channel, in mice and rats. Neurosci. Biobehav. Rev (1999) 23:1087–1110.
  • BENINGTONJH, WOUDENBERG MC, HELLER HC: Apamin, a selective SK potassium channel blocker, suppresses REM sleep without a compensatory rebound. Brain Res. (1995) 692:86–92.
  • GANDOLFO G, SCHWEITZ H, LAZDUNSKI M, GOTTESMANN C: Sleep cycle disturbances induced by apamin, a selective blocker of Ca(2+)-activated K+ channels. Brain Res. (1996) 736:344–347.
  • CAMPOS RJ, ROSA J, GALANAKIS D et al.: Synthesis, molecular modeling, and pharmacological testing of bis-quinolinium cyclophanes: potent, non-peptidic blockers of the apamin-sensitive Ca(2+)-activated K(+) channel.j Med. Chem. (2000) 43:420–431.
  • CHEN JQ, GALANAKIS D, GANELLIN CR et al: bis-Quinolinium cyclophanes: 8,14-diaza-1,7(1, 4)-diquinolinacyclo-tetradecaphane (UCL 1848), a highly potent and selective, nonpepticlic blocker of the apamin-sensitive Ca(2+)-activated K(+) channel.' Med. Chem. (2000) 43:3478–3481.
  • MARRION NV: Control of M-current. Ann. Rev Physiol. (1997) 59:483–504.
  • SCHROEDER BC, HECHENBERGER M, WEINREICH F, KUBISCH C, JENTSCH TJ: KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents. " Biol. Chem. (2000) 275:24089–24095.
  • SELYANKO AA, HADLEY JK, WOOD IC et al.: Inhibition of KCNQ1-4 potassium channels expressed in mammalian cells via M1 muscarinic acetylcholine receptors. Physiol. (2000) 522 Pt 3:349–355.
  • BIERVERT C, SCHROEDER BC, KUBISCH C et al.: A potassium channel mutation in neonatal human epilepsy. Science (1998) 279:403–406.
  • CHARLIER C, SINGH NA, RYAN SG et al.: A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat. Gen. (1998) 18:53–55.
  • SINGH NA, CHARLIER C, STAUFFER D et al.: A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet. (1998) 18:25–29.
  • WANG HS, BROWN BS, MCKINNON D, COHEN IS: Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991. Mol. Pharmacol. (2000) 57:1218–1223.
  • SCHNEE ME, BROWN BS: Selectivity of linopirdine (DuP 996), a neurotransmitter release enhancer, in blocking voltage-dependent and calcium-activated potassium currents in hippocampal neurons. J. Pharmacol. Exp. Ther: (1998) 286:709–717.
  • ZACZEK R, CHORVAT RJ, SAYE JA et al.: Two new potent neurotransmitter release enhancers, 10,10-bis(4-pyridinylmethyl) -9 (10H)-anthracenone and 10,10-bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone: comparison to linopirdine. I Pharmacol. Exp. The]: (1998) 285:724–730.
  • PIENIASZEK HJ Jr, FISKE WD, SAXTON TD et al.: Single-dose pharmacokinetics, safety, and tolerance of linopirdine (DuP 996) in healthy young adults and elderly volunteers. J. Clin. Pharmacol. (1995) 35:22–30.
  • EARL RA, ZACZEK R, TELEHA CA et al.: 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action. I Med. Chem. (1998) 41:4615–4622.
  • MAIN MJ, CRYAN JE, DUPERE JR et al.: Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol. (2000) 58:253–262.
  • WICKENDEN AD, YU W, ZOU A, JEGLA T, WAGONER PK: Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol. (2000) 58:591–600.
  • NAGAKI N, GONOI T, CLEMENT JP et al: A family of sulfonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron (1996) 16:1011–1017.
  • HEURTEAUX C, BERTAINA V, WIDMANN C, LAZDUNSKI M: K+ channel openers prevent global ischemia-induced expression of c-fos, c-jun, heat shock protein, and amyloidP-protein precursor genes and neuronal death in rat hippocampus. Proc. Natl. Acad. Sci. USA (1993) 90:9431–9435.
  • GOODMAN Y, MATTSON MP: K+ channel openers protect hippocampal neurons against oxidative injury and amyloid beta-peptide toxicity. Brain Res. (1996) 706:328–332.
  • HERNANDEZ-SANCHEZ C, BASILE AS, FEDOROVA et al: Mice transgenically overexpressing sulfonylurea receptor 1 in forebrain resist seizure induction and excitotoxic neuron death. Proc. Natl Acad. Sci. USA (2001) 98:3549–3554.
  • OCANA M, BARRIOS M, BAEYENS JM: Cromakalim differentially enhances antinociception induced by agonists of a(2)adrenoceptors, y-aminobutyric acid(B), 11 and lc opioid receptors. I Pharmacol. Exp. The]: (1996) 276:1136–1142.
  • GALEOTTI N, GHELARDINI C, CALDARI B, BARTOLINI A: Effect of potassium channel modulators in mouse forced swimming test. Br. J. Pharmacol. (1999) 126:1653–1659.
  • GUO W, TODD K, BOURIN M, HASCOET M, KOUADIO F: Additive effects of glyburide and antidepressants in the forced swimming test: evidence for the involvement of potassium channel blockade. Pharmacol. Biochem. Behav. (1996) 54:725–730.
  • REDROBE JP, PINOT P, BOURIN M: The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Fundam. Clin. Pharmacol. (1996) 10:524–528.
  • KOURRICH S, MOURRE C, SOUMIREU-MOURAT B: Kaliotoxin, a Kv1.1 and Kv1.3 channel blocker, improves associative learning in rats. Behav. Brain Res. (2001) 120:35–46.
  • MEIRI N, GHELARDINI C, TESCO G et al.: Reversible antisense inhibition of Shaker-like Kv1.1 potassium channel expression impairs associative memory in mouse and rat. Proc. Nati Acad. Sci. USA (1997) 94:4430–4434.
  • SMART SL, LOPANTSEV V, ZHANG CL et al.: Deletion of the K(V)1.1 potassium channel causes epilepsy in mice. Neuron (1998) 20:809–819.
  • CLARK JD, TEMPEL BL: Hyperalgesia in mice lacking the Kv1.1 potassium channel gene. Neurosci. Lett. (1998) 251:121–124.
  • DOYLE DA, MORAIS CJ, PFUETZNER RA eta].: The structure of the potassium channel: molecular basis of K± conduction and selectivity. Science (1998) 280:69–77.
  • •Significant publication on the elucidation of the crystal structure of the KcsA K± channel.

Websites

  • www.iddb3.com IDdb database. Drug report on Flindokalner (BMS-204352). Information extracted from page last updated 1st November 2002.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.